Selling, General, and Administrative Costs: Johnson & Johnson vs Dynavax Technologies Corporation

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, the financial strategies of companies can be as varied as their product lines. Johnson & Johnson, a titan in the industry, and Dynavax Technologies Corporation, a smaller yet innovative player, offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Johnson & Johnson consistently allocated a significant portion of its budget to SG&A, with expenses peaking at approximately $22 billion in 2018. This reflects their expansive global operations and robust marketing strategies. In contrast, Dynavax's SG&A expenses, while much smaller, have shown a remarkable growth trajectory, increasing by over 750% from 2014 to 2023. This surge underscores Dynavax's aggressive push to expand its market presence and invest in administrative capabilities. The data highlights the diverse financial strategies employed by these companies in navigating the competitive pharmaceutical landscape.